Omniab, Inc. (OABI) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Omniab, Inc. (OABI) stock forecast summary
Our AI ranks Omniab, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Omniab, Inc. is a small-cap company with a market capitalization of $683M. It ranks number 7 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its D/E Ratio of 0.12x is the lowest of the 11 peers that report one.
A per-ticker accuracy statistic for OABI is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OABI included.
Follow OABI freeOABI price chart and AI forecast
How OABI ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Omniab, Inc. (OABI) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | OABI | Rank |
|---|---|---|
| Market Cap | $683M | 7/12 |
| P/B Ratio | 2.63x | 6/8 |
| EPS | $-0.47 | – |
| Book Value/Share | $1.79 | – |
| Revenue/Share | $0.26 | – |
| FCF/Share | $-0.12 | – |
Profitability & Margins
| Metric | OABI | Rank |
|---|---|---|
| ROE | -17.0% | 6/10 |
| ROA | -15.2% | 6/13 |
| ROIC | -17.5% | 10/12 |
| Operating Margin | -125.8% | 7/13 |
| Net Margin | -115.1% | 7/11 |
| EBT Margin | -118.9% | 8/13 |
| Tax Rate | 3.1% | – |
Financial Health
| Metric | OABI | Rank |
|---|---|---|
| Current Ratio | 4.80x | 3/16 |
| Quick Ratio | 4.72x | 2/6 |
| D/E Ratio | 0.12x | 11/11 |
| Financial Leverage | 1.12x | 11/11 |
| Working Capital | $52M | 5/15 |
Cash Flow
| Metric | OABI | Rank |
|---|---|---|
| Operating Cash Flow | -$18M | 13/15 |
| Free Cash Flow | -$18M | 5/7 |
| Capital Spending | -$470K | 2/7 |
| FCF/Sales | -47.2% | 5/8 |
| CapEx/Sales | 1.2% | 8/8 |
Operational Efficiency
| Metric | OABI | Rank |
|---|---|---|
| Asset Turnover | 0.13x | 8/9 |
| Receivables Turnover | 3.7x | 7/7 |
| Fixed Assets Turnover | 4.5x | 5/9 |
| Days Sales Outstanding | 98 days | 1/7 |
Income Statement
| Metric | OABI | Rank |
|---|---|---|
| Total Revenue | $38M | 5/8 |
| Operating Income | -$48M | 14/15 |
| Net Income | -$44M | 11/13 |
| R&D Expense | $44M | 3/7 |
Dividend & Shareholder Information
| Metric | OABI | Rank |
|---|---|---|
| Shares Outstanding | 145M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $66M | 22.7% of assets |
| Cash & Short-term Investments | $24M | 8.4% of assets |
| Accounts Receivable | $10M | 3.6% of assets |
| Inventory | $1M | 0.3% of assets |
| Total Liabilities | $30M | 10.3% of assets |
| Short-term Debt | $12M | 4.0% of assets |
OABI quarterly financials and insider trading
Omniab, Inc. (OABI) industry peers
Companies classified under the same SEC industry code as Omniab, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| OABI Omniab, Inc. | ▲ | $683M |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $24M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▶ | $3M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Where OABI sits on the market map
Omniab, Inc. (OABI) stock news
Loading...
Omniab, Inc. (OABI) stock forecast FAQ
What is the Omniab, Inc. (OABI) stock forecast?
Our AI ranks Omniab, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Omniab, Inc. stock predictions?
A per-ticker accuracy statistic for OABI is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Omniab, Inc. forecasts updated?
Omniab, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Omniab, Inc.'s industry peers?
16 issuers in our coverage, OABI included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.